{"id":8344,"date":"2025-08-16T00:49:47","date_gmt":"2025-08-15T21:49:47","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8344"},"modified":"2025-08-16T00:49:47","modified_gmt":"2025-08-15T21:49:47","slug":"triple-biomarker-risk-pathway-ldl-hs-crp-lpa","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/triple-biomarker-risk-pathway-ldl-hs-crp-lpa\/","title":{"rendered":"Triple-Biomarker Risk Pathway ( LDL\u00a0 + hs-CRP + Lp(a))"},"content":{"rendered":"
Triple-Biomarker Risk Pathway ( LDL\u00a0 + hs-CRP + Lp(a))<\/div>\n
<\/div>\n
Medical News Summary, based on an article published in the 2025 European Heart Journal (doi:10.1093\/eurheartj\/ehaf209)<\/div>\n
<\/div>\n
1) Who to test (one-time \u201ctriple test\u201d)<\/div>\n
1. Primary prevention: Adults 30\u201375 at borderline\/intermediate risk, risk-enhancing factors, family history of premature ASCVD, or uncertainty after standard calculators.<\/span><\/div>\n
2. Secondary prevention: All patients with established ASCVD (for residual inflammatory or thrombotic risk profiling).<\/span><\/div>\n
<\/div>\n
2) How to measure & interpret<\/div>\n
1. LDL : Standard fasting\/non-fasting lab; treat to targets (see Actions below).<\/span><\/div>\n
2. hs-CRP:<\/span><\/div>\n
\u2022 Measure twice, \u22652 weeks apart, when clinically well (no infection\/trauma).<\/span><\/div>\n
\u2022 Cut-points: \u22652 mg\/L = elevated (residual inflammatory risk). \u226510 mg\/L \u2192 search for non-CV inflammatory causes, repeat when well.<\/span><\/div>\n
3. Lp(a):<\/span><\/div>\n
\u2022 Once-in-a-lifetime test (genetically fixed).<\/span><\/div>\n
\u2022 High: \u2265125 nmol\/L (\u2248 \u226550 mg\/dL)*; Intermediate: 30\u2013124 nmol\/L; Low: <30 nmol\/L.<\/span><\/div>\n
\u2022 Consider cascade screening of first-degree relatives if high.<\/span><\/div>\n
*Conversion mg\/dL\u2194\ufe0fnmol\/L varies by assay; use lab-reported reference.<\/div>\n
<\/div>\n
3) Combine results into a simple risk tier<\/div>\n
<\/div>\n
Count how many are \u201celevated\u201d: LDL above goal, hs-CRP \u22652 mg\/L, Lp(a) \u2265125 nmol\/L.<\/div>\n
<\/div>\n
4) Practical action steps<\/div>\n
<\/div>\n
A) LDL\u2013centered (both primary & secondary)<\/div>\n
1. High-intensity statin to reach goal.<\/span><\/div>\n
2. If above goal: add ezetimibe \u2192 PCSK9 inhibitor (or bempedoic acid if statin-intolerant\/adjunct).<\/span><\/div>\n
3. Targets (choose per guideline you follow):<\/span><\/div>\n
\u2022 Very-high risk: LDL-C <55 mg\/dL (ESC) or <70 mg\/dL (ACC).<\/span><\/div>\n
\u2022 Consider apoB (<65 mg\/dL very-high risk) where available.<\/span><\/div>\n
B)Inflammation-centered (hs-CRP \u22652 mg\/L after LDL at goal)<\/div>\n
1. First line: Lifestyle \u201cbundle\u201d (weight loss, Mediterranean-style diet, exercise, smoking cessation, sleep, periodontal care, vaccines).<\/span><\/div>\n
2. Drug options (select patients):<\/span><\/div>\n
\u2022 Colchicine 0.5 mg daily (secondary prevention; avoid in significant CKD\/hepatic disease, drug interactions; counsel on GI effects).<\/span><\/div>\n
\u2022 Bempedoic acid lowers LDL\u00a0 and hs-CRP (useful in statin intolerance or as add-on).<\/span><\/div>\n
C) Lp(a)\u2013centered<\/div>\n
1. If Lp(a) \u2265125 nmol\/L (\u2248 \u226550 mg\/dL):<\/span><\/div>\n
\u2022 Tight LDL control (often lower than usual targets).<\/span><\/div>\n
\u2022 Consider PCSK9 inhibitor (modest Lp(a) lowering; outcome benefit driven largely by LDL reduction).<\/span><\/div>\n
\u2022 Family screening; discuss trial eligibility for antisense\/siRNA Lp(a) agents where available.<\/span><\/div>\n
<\/div>\n
D) Role of CAC (primary prevention)<\/div>\n
\u2022 Use CAC when treatment decisions remain uncertain.<\/span><\/div>\n
\u2022 CAC=0: consider de-escalation (except smokers, diabetes, strong FH).<\/span><\/div>\n
\u2022 CAC\u2265100 (or \u226575th percentile): favors statins and tighter control regardless of hs-CRP.<\/span><\/div>\n
<\/div>\n
5) One-page takeaway (Doctor\u2019s talking points )<\/div>\n
1. Order LDL-C + hs-CRP (\u00d72) + Lp(a) once.<\/span><\/div>\n
2.\u00a0 Treat LDL-C to goal (statin \u00b1 ezetimibe \u00b1 PCSK9i \/ bempedoic).<\/span><\/div>\n
3. If hs-CRP \u22652 mg\/L despite LDL at goal \u2192 lifestyle first, then consider colchicine (secondary prevention).<\/span><\/div>\n
4. If Lp(a) high \u2192 tighten LDL-C goal, PCSK9i as needed, family screening.<\/span><\/div>\n
5. Use CAC when primary-prevention decisions are uncertain.<\/span><\/div>\n
6. Re-check lipids at 4\u201312 weeks; hs-CRP once to confirm; don\u2019t repeat Lp(a).<\/span><\/div>\n
<\/div>\n
https:\/\/doi.org\/10.1093\/eurheartj\/ehaf209<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Triple-Biomarker Risk Pathway ( LDL\u00a0 + hs-CRP + Lp(a)) Medical News Summary, based on an article published in the 2025 European Heart Journal (doi:10.1093\/eurheartj\/ehaf209) 1) Who to test (one-time \u201ctriple test\u201d) 1. Primary prevention: Adults 30\u201375 at borderline\/intermediate risk, risk-enhancing factors, family history of premature ASCVD, or uncertainty after standard calculators. 2. Secondary prevention: All […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8344","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8344","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8344"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8344\/revisions"}],"predecessor-version":[{"id":8345,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8344\/revisions\/8345"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8344"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8344"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8344"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}